Literature DB >> 31439180

A study of clinical profile of cases of MDR-TB and evaluation of challenges faced in initiation of second line Anti tuberculosis treatment for MDR-TB cases admitted in drug resistance tuberculosis center.

Suneel Mukati1, Arti Julka2, H G Varudkar2, Mustafa Singapurwala2, J C Agrawat2, Deepali Bhandari2, Anukool Jain2.   

Abstract

OBJECTIVES: To study the clinical profile of cases, evaluation of comorbidities and problems encountered in initiation of second-line drugs for multidrug-resistant tuberculosis (MDR-TB) patients.
METHODOLOGY: A prospective observational study was conducted on MDR patients admitted in drug resistance tuberculosis (DRTB) center of RDGMC Surasa Ujjain, a rural medical college, over a span of one year.
RESULTS: Out of 130 admitted cases, majority (30%) were between 31 and 40 years of age. Males were predominant (70%). Females were significantly younger compared to males (p=0.00308). Most patients (83.8%) were underweight (body mass index (BMI)<18.5kg/m2). According to MDR-TB suspect criteria, majority were defaulter cases (39.23%). The anemia was the most common comorbidity (73.84%) among the study group followed by diabetes mellitus (9.23%), chronic obstructive pulmonary disease (COPD) (9.23%), 10 (7.69) asthma, 10 (7.69%) thyroid disease 9 (6.92%) followed by respiratory insufficiency 4 (3%), HIV 2 (1.5%), deep venous thrombosis (DVT) 2 (1.5%), renal failure 2 (1.5%), and hepatic failure 1 (0.76%). Majority had minimal lesion - 57 (43.8%), moderate - 38 (29.2%), and moderate advanced - 23 (17.7%) while far advanced was noted on X-rays in 12 (9.2%). A total of 91 (70%) cases had non-cavitary lesions and 39 (30%) had cavitary lesions, of which 27 were unilateral and 12 were bilateral.
CONCLUSION: The males were predominant in our study however females were affected at a younger age compared to the males. Most of the patients had taken Anti tuberculosis treatment (ATT) from Revised National Tuberculosis Control Program (RNTCP) in which defaulter and relapse were the major contributors of MDR-TB cases in our study. Radiological extent of lesions of these patients was less than expectation. Management of comorbidities is essential for compliance to treatment. It necessitates prolonged hospitalization and requires frequent follow-up in the DRTB center.
Copyright © 2016 Tuberculosis Association of India. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Clinical profile; Comorbidities; Multidrug-resistant tuberculosis (MDR-TB); Radiological lesion

Mesh:

Substances:

Year:  2017        PMID: 31439180     DOI: 10.1016/j.ijtb.2016.11.031

Source DB:  PubMed          Journal:  Indian J Tuberc        ISSN: 0019-5707


  4 in total

1.  Application of KTH-integrated nursing model in care of patients with multi-drug resistant tuberculosis.

Authors:  Hanfen Wei; Xiaoqian Duan
Journal:  Am J Transl Res       Date:  2021-06-15       Impact factor: 4.060

2.  Tuberculosis related disability: a systematic review and meta-analysis.

Authors:  Kefyalew Addis Alene; Kinley Wangdi; Samantha Colquhoun; Kudakwashe Chani; Tauhid Islam; Kalpeshsinh Rahevar; Fukushi Morishita; Anthony Byrne; Justin Clark; Kerri Viney
Journal:  BMC Med       Date:  2021-09-09       Impact factor: 8.775

3.  Incidence and predictors of mortality among persons receiving second-line tuberculosis treatment in sub-Saharan Africa: A meta-analysis of 43 cohort studies.

Authors:  Dumessa Edessa; Fuad Adem; Bisrat Hagos; Mekonnen Sisay
Journal:  PLoS One       Date:  2021-12-10       Impact factor: 3.240

4.  Malnutrition prevalence and associated biochemical factors among drug-resistance tuberculosis (DR-TB) patients at key treatment sites in Conakry City, Republic of Guinea.

Authors:  Aboubacar Sidiki Magassouba; Almamy Amara Touré; Boubacar Djelo Diallo; Lansana Mady Camara; Demba Touré; Nfanly Conté; Macka Diaby; Soriba Naby Camara; Gnoume Camara; Adama Marie Bangoura; Tamba Alima Kamano; Adrien Fapeingou Tounkara
Journal:  Pan Afr Med J       Date:  2021-03-17
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.